CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03919175
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:19.957313+00:00
Published At: 2026-02-27T00:00:00+00:00
Record Updated At: 2026-02-27
Results Posted At: 2026-02-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoma", "Follicular Lymphoma", "Follicular Lymphoma, Grade 1", "Follicular Lymphoma Grade 2", "Follicular Lymphoma Grade IIIa", "Marginal Zone Lymphoma", "Marginal Zone B Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-27"
protocolSection.identificationModule.nctId: "NCT03919175"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-02-27"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.